Navigation Links
DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
Date:9/24/2009

PRINCETON, N.J., Sept. 24 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.

Under the terms of the agreements, DOR will sell approximately 15,200,000 common shares together with a five-year warrant to purchase up to approximately 7,600,000 shares of DOR common stock at $0.278 per share, for an aggregate price of approximately $3.85 million ($0.253 per share representing the market price of DOR's common stock as measured by its five- day trailing average as of September 22, 2009). The expiration date of the warrants will be accelerated if the Company's common stock meets certain price thresholds and DOR would receive additional gross proceeds of approximately $2.11 million if exercised.

"We are pleased with this vote of confidence and support from our partner Sigma-Tau and the institutional investors," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of DOR. "This financing is designed to provide the fuel to complete our confirmatory Phase 3 clinical study of orBec(R) in the treatment of acute GI GVHD, an unmet medical need. We are looking forward to the imminent initiation of this trial."

The Company's common stock will be sold to accredited investors in a private placement in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). The shares will not be registered under the Securities Act or any state securities laws, and the shares may not be offered or sold by the investors absent registration or an applicable exemption from the registration requirements of th
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
3. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
4. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
7. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
8. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 ... highlighting the success of the prescription drug benefit, commonly referred to as Part D. ... and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... announces that a new market research report is ... Optoelectronics Industry http://www.reportlinker.com/p087331/Global-Optoelectronics-Industry.html ... for Optoelectronics in Millions of US$ by the ... Optical Components. Major segments analyzed under the Optical ...
... Inc. (Pink Sheets: SNDY ) is pleased ... meeting held September 28, 2010 near Solos, headquarters in ... Amanda Segersten and Fred Schiemann were re-elected to serve ... shareholders meeting. The shareholders also approved the motion to ...
Cached Medicine Technology:Reportlinker Adds Global Optoelectronics Industry 2Reportlinker Adds Global Optoelectronics Industry 3Reportlinker Adds Global Optoelectronics Industry 4Reportlinker Adds Global Optoelectronics Industry 5Reportlinker Adds Global Optoelectronics Industry 6Reportlinker Adds Global Optoelectronics Industry 7Reportlinker Adds Global Optoelectronics Industry 8Reportlinker Adds Global Optoelectronics Industry 9Reportlinker Adds Global Optoelectronics Industry 10Reportlinker Adds Global Optoelectronics Industry 11Reportlinker Adds Global Optoelectronics Industry 12Reportlinker Adds Global Optoelectronics Industry 13Reportlinker Adds Global Optoelectronics Industry 14Reportlinker Adds Global Optoelectronics Industry 15Reportlinker Adds Global Optoelectronics Industry 16Reportlinker Adds Global Optoelectronics Industry 17Reportlinker Adds Global Optoelectronics Industry 18Reportlinker Adds Global Optoelectronics Industry 19Reportlinker Adds Global Optoelectronics Industry 20Reportlinker Adds Global Optoelectronics Industry 21Reportlinker Adds Global Optoelectronics Industry 22Reportlinker Adds Global Optoelectronics Industry 23Reportlinker Adds Global Optoelectronics Industry 24Reportlinker Adds Global Optoelectronics Industry 25Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting 2
(Date:7/30/2015)... ... ... As more hospitals across the country see the value in developing their ... of growing competition, it is more important than ever to market a hospital’s ... at Wound Care Advantage has found that while many hospitals already have ...
(Date:7/30/2015)... ... ... OSF Healthcare System has been recognized as one of the nation’s ... & Health Networks. This marks the fourth consecutive year for this achievement by the ... Third Order of St. Francis . , Health data security and patient engagement are ...
(Date:7/30/2015)... ... ... between a healthy head of hair and a feeling of confidence is a powerful one ... have a devastating impact on the daily life of a person. From increased anxiety ... hair loss are not to be taken lightly. , The skilled staff at Parsa Mohebi ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life has ... go. With no water needed, the refreshing berry-flavored tablets are the perfect travel ... the natural ingredients that may help with body detoxification, protection and hydration,” said ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... software, TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3
... eye cancer is greater among kidney transplant patients and ... public, which suggests the disease is associated with immune ... of New South Wales in Sydney and colleagues compared ... general population with that of kidney transplant patients, who ...
... apo A-I ratio is not a better predictor of ... include total cholesterol and HDL-C, according to a study ... risk-prediction instruments and guidelines for coronary heart disease (CHD) ... total cholesterol, or both for CHD risk assessment. But ...
... parents informational handouts can improve their understanding of the ... according to a recent study conducted by researchers from ... School of Medicine in New Haven, CT. , Like ... about the increasing radiation exposure to children caused by ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
... tell us when middle-aged spread is getting out of hand. ... the ready. New research shows that adding several inches to ... rangemarkedly increases the risk of unhealthy plaque build-up in the ... , The research, conducted at the University of Texas Southwestern ...
... indicates that the loss of two types of brain ... of symptoms associated with Parkinson,s disease. , The evidence, ... loss of both norepinephrine and dopamine neurons and the ... was originally thought that the loss of only dopamine ...
Cached Medicine News:Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2Health News:Pot bellies linked to early signs of cardiovascular disease 2Health News:Pot bellies linked to early signs of cardiovascular disease 3Health News:Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinson's symptoms 2
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
... utilizes a new, improved format that requires only ... detection. The testing device employs innovative lateral flow ... already been applied to the testing strip. Workflow ... results shown by the appearance of an easy-to-read ...
Medicine Products: